Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure

被引：0
|
作者：
Hochhaus, A.
Mueller, M.
Cortes, J. E.
Kim, D.
Matlob, Y.
Ploughman, L.
Hughes, T.
机构：
[1] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Catholic Univ Korea, Seoul, South Korea
[4] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[5] Bristol Myers Squibb, Pennington, NJ USA
[6] Inst Med & Vet Sci, Adelaide, SA 5000, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.7014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Hardling, M
    Wei, Y
    Palmqvist, L
    Swolin, B
    Stockelberg, D
    Gustavsson, B
    Ekeland-Sjöberg, K
    Wadenvik, H
    Ricksten, A
    MEDICAL ONCOLOGY, 2004, 21 (04) : 349 - 358
  • [22] Induction of BCR-ABL mutations for acquired resistance in chronic myelogenous leukemia cells by imatinib
    Yuan, Hongfeng
    Gao, Chunggang
    Bhatia, Ravi
    Chen, WenYong
    CANCER RESEARCH, 2009, 69
  • [23] Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William G.
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary Beth
    Pierce, Sherry
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [24] BCR-ABL TYROSINE KINASE DOMAIN MUTATIONS COMBINATIONS AFFECTS IMATINIB RESISTENCE IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
    Bintoro, S. U. Y.
    Amrita, P. N. A.
    Joewarini, E.
    Suryohusodo, P.
    Soebandiri, S.
    NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (04): : 53 - 58
  • [25] Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls
    Kantarjian, H
    O'Brien, S
    Cortes, J
    Giles, F
    Shan, JQ
    Rios, MB
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Wierda, W
    Kornblau, S
    Ferrajoli, A
    Keating, M
    Talpaz, M
    CLINICAL CANCER RESEARCH, 2004, 10 (01) : 68 - 75
  • [26] Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
    Radich, Jerald P.
    Martinelli, Giovanni
    Hochhaus, Andreas
    Gottardi, Enrico
    Soverini, Simona
    Branford, Susan
    Mueller, Martin C.
    Beppu, Lan
    Shou, Yaping
    Haque, Ariful
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Hughes, Timothy P.
    Kim, Dong-Wook
    Saglio, Giuseppe
    BLOOD, 2009, 114 (22) : 464 - 465
  • [27] Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety
    Khoury, H. J.
    Goldberg, S. L.
    Mauro, M. J.
    Stone, R. M.
    Matloub, Y.
    Chen, T.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] DASATINIB LACK OF CROSS INTOLERANCE TO IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO ARE INTOLERANT TO IMATINIB - A RETROSPECTIVE SAFETY ANALYSIS
    Guilhot, E.
    Goldberg, S. L.
    Stone, R. M.
    Mauro, M.
    Matloub, Y.
    Chen, T. T.
    Khoury, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 51 - 51
  • [29] BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Kim, D.
    Saglio, G.
    Martinelli, G.
    Shou, Y.
    Stein, A. M.
    Woodman, R. C.
    Kantarjian, H.
    Hughes, T. P.
    Radich, J. P.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)
    Mauro, M. J.
    Baccarani, M.
    Cervantes, F.
    Lipton, J. H.
    Matloub, Y.
    Sinha, R.
    Stone, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345